Alpha-Lipoic Acid Encyclopedia — Scientific Background

What Is Alpha-Lipoic Acid?

Alpha-lipoic acid (ALA), also known as thioctic acid or 1,2-dithiolane-3-pentanoic acid, is an organosulfur compound synthesized from octanoic acid in the mitochondria of plant and animal cells. It is a disulfide-containing compound derived from octanoic acid that is synthesized in mitochondria and found in microorganisms, plants, and animals. The molecule contains two sulfur atoms connected by a disulfide bond.

The R- vs. S- Enantiomers

ALA contains a chiral carbon and exists as two enantiomers: R-α-lipoic acid (RLA), which occurs naturally, and S-α-lipoic acid (SLA), which can be produced synthetically. RLA showed higher plasma concentration than SLA. After oral and intraduodenal administration of the racemic mixture to pylorus-ligated rats, the AUCs of RLA were significantly about 1.24 and 1.32 times higher than that of SLA. The enantioselective pharmacokinetics of LA in rats arose from the fraction absorbed multiplied by gastrointestinal availability (FaFg) and hepatic availability (Fh), and not from the total clearance.

In a human pharmacokinetic study, oral bioavailability (Fabs) of the enantiomers from an oral solution was calculated to be 38±15% and 28±14% for R(+)- and S(−)-α-LA, respectively (P<0.001). The mean total plasma clearance of R(+)-α-LA was 12.24±2.62 ml min⁻¹ kg⁻¹, significantly different from S(−)-α-LA at 15.64±4.18 ml min⁻¹ kg⁻¹ (P<0.001).

Physiological Functions

Mitochondrial Enzyme Cofactor

ALA is a necessary cofactor for mitochondrial α-ketoacid dehydrogenases, serving a critical role in mitochondrial Energy Metabolism. It is covalently bound to the ε-amino group of lysine residues and functions as a cofactor for mitochondrial enzymes by catalyzing the oxidative decarboxylation of pyruvate, α-ketoglutarate, and branched-chain α-keto acids. ALA is a cofactor that covalently binds to mitochondrial enzymes, such as pyruvate dehydrogenase (PDH) and oxoglutarate dehydrogenase (OGDH). ALA is not only crucial to the function of major enzymes that provide carbon to the tricarboxylic acid cycle but also has strong antioxidant properties.

The Ideal Antioxidant

ALA and its reduced form DHLA meet all the criteria for an “ideal antioxidant” because they can easily quench radicals, can chelate metals, have an amphiphilic character, and they do not exhibit any serious side effects. They interact with other antioxidants and can regenerate them. For this reason, LA is called an “antioxidant of antioxidants”. LA has an influence on the second messenger nuclear factor κB (NF-κB) and attenuates the release of free radicals and cytotoxic cytokines.

Blood Sugar and Metabolic Support

ALA has been shown to improve glucose and ascorbate handling, increase eNOS activity, activate Phase II detoxification via the transcription factor Nrf2, and lower expression of MMP-9 and VCAM-1 through repression of NF-kappa B. Beneficial effects are achieved with low micromolar levels of LA, suggesting that some of its therapeutic potential extends beyond the strict definition of an antioxidant.

Neuroprotective Effects

Preclinical and clinical evidence suggests that LA modulates several signalling pathways associated with oxidative stress, inflammation, and neuronal injury. In animal models, LA has demonstrated attenuated neuroinflammation by suppressing pro-inflammatory cytokines (e.g., IL-1β), modulating microglial and astrocytic activation, and restoring antioxidant defences. LA has demonstrated direct anticonvulsant effects by reducing seizure frequency, mitigating behavioural and cognitive impairments, and downregulating immediate-early gene expression such as Nrf2 in pentylenetetrazol-induced seizure models.

Cardioprotective Effects

ALA has been shown to have a protective effect on the cardiovascular system. The specific mechanisms may involve an anti-oxidative stress role by scavenging reactive oxygen species, regulation of aldehyde dehydrogenase-2 (ALDH2), and anti-inflammatory properties.

The Bioavailability Challenge

Despite its essential physiological functions, native ALA presents significant bioavailability challenges. The compound has poor water solubility and heat sensitivity, which further challenges its delivery. RLA is poorly soluble and has stability problems under acidic conditions, limiting its clinical applications. Following oral administration, the plasma half-life of ALA enantiomers is short, approximately 0.32–0.37 hours, and absolute bioavailability from an oral solution is 28–38%.

Liposomal Alpha-Lipoic Acid

liposomal encapsulation of ALA provides a fundamentally different delivery mechanism from conventional forms. The phospholipid bilayer surrounds the ALA molecule, forming a shield that protects it from gastric acid degradation and enzymatic metabolism. This delivery system:

• Prevents degradation of RLA under acidic conditions (pH 1.2) and simulated gastric fluid (pH 1.5)

• Enhances intestinal absorption through lipid-mediated pathways

• Increases systemic exposure of RLA and its reduced form DHLA by 2.8- and 5.8-fold, respectively

• Provides sustained release through phospholipid lipolysis by intestinal lipase

A novel delivery system using electrospun nanofiber proliposomes for on-demand LA delivery has been developed to overcome low aqueous solubility and heat sensitivity. The nanofibers derived liposomes exhibited ∼143 nm in size with a low polydispersity index and demonstrated excellent physicochemical stability up to one month. The in vitro release studies demonstrated biphasic release of LA from the liposomal nanofibrous matrix.

Clinical Evidence

Diabetic Neuropathy

A randomized controlled parallel study evaluated 58 type 2 diabetic patients with diabetic neuropathy. Patients were randomly allocated to receive either 500 mcg/day of oral roflumilast or 600 mg/day of oral ALA for 12 weeks. After intervention, the ALA group showed significant decreases in HbA1c by 0.3% (3.8% relative reduction), fasting blood glucose, fasting insulin level, HOMA-IR, and serum levels of TNF-α, MDA, and neurotensin (P<0.001). Both groups exhibited significant reductions in neuropathy scores (P<0.001).

Bioavailability Evidence

In a human pharmacokinetic study using a specific enantioselective HPLC assay, single doses of 200 mg racemic α-LA were administered to twelve healthy volunteers orally and intravenously in random order. The IV infusion resulted in mean peak plasma levels (Cmax) of 13.0 μg/ml for R(+)- and 11.6 μg/ml for S(−)-α-LA (P<0.001). After oral dosage, highest Cmax values were observed for the oral solution with 1.95 μg/ml for R(+)-α-LA. The absolute bioavailability of the enantiomers from the oral solution was calculated to be 38±15% and 28±14% for R(+)- and S(−)-α-LA, respectively (P<0.001).

Metabolic Syndrome

A meta-analysis of randomized controlled trials evaluated ALA for diabetic peripheral neuropathy. Studies generally used 600, 1,200, or 1,800 mg of ALA, and it remains unclear if higher doses reliably lead to greater effects. A systematic review encompassing varying dosages (600–1,800 mg/day) and treatment durations (3 to 208 weeks) for diabetic peripheral neuropathy has been conducted.

Safety and Regulatory

Alpha-lipoic acid is generally well tolerated at commonly used doses. Clinical trials have used ALA at doses of 600 mg/day for 12 weeks without serious adverse effects. Higher doses of 1,200–1,800 mg/day have been evaluated in clinical studies, though it remains unclear if higher doses reliably lead to greater effects. ALA is widely commercialized as a dietary supplement ingredient and pharmaceutical agent. In Germany, ALA is approved as a drug for the treatment of diabetic neuropathy. Testing protocols must adhere to international standards including USP, European Pharmacopoeia, and FAO/WHO Codex Alimentarius. Formulators should verify local regulatory requirements prior to market entry.

This product is intended for research, nutraceutical, and functional food applications. Not intended to diagnose, treat, cure, or prevent any disease.

109$/KG

99$/KG